(Q37017272)

17 August 2017

4 references

13 March 2019

24 March 2019

12 November 2019

16 July 2021

Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women (English)

1 reference

organic compound, having C-P covalent bound

17 August 2017

3 references

13 March 2019

24 March 2019

12 November 2019

1 reference

PubMed

bone density conservation agents

12 November 2019

1 reference

16 July 2021

Philip Sambrook

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

Clinical Interventions in Aging

17 August 2017

5 references

17 August 2017

13 March 2019

24 March 2019

12 November 2019

16 July 2021

2

1 reference

17 August 2017

1

1 reference

17 August 2017

65-72

1 reference

Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2684081

Ibandronate: a clinical pharmacological and pharmacokinetic update

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2684081

Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2684081

Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2684081

Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2684081

Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2684081

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2684081

Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2684081

Efficacy and safety of ibandronate given by intravenous injection once every 3 months

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2684081

Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2684081

The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2684081

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2684081

Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2684081

Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2684081

Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2684081

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2684081

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2684081

Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results

4 December 2018

1 reference

https://api.crossref.org/works/10.2147%2FCIIA.2007.2.1.65

Renal failure associated with intravenous diphosphonates

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FCIIA.2007.2.1.65

Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FCIIA.2007.2.1.65

Renal safety of intravenous ibandronic Acid in breast cancer patients with metastatic bone disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FCIIA.2007.2.1.65

BM 21.0955, a potent new bisphosphonate to inhibit bone resorption

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FCIIA.2007.2.1.65

Acute renal failure associated with the administration of parenteral etidronate

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FCIIA.2007.2.1.65

Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.2147%2FCIIA.2007.2.1.65

31 March 2020

Identifiers

DOI

10.2147/CIIA.2007.2.1.65

1 reference

release_5xxxgstztve2rnypwjvgpwpw5i

17 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5xxxgstztve2rnypwjvgpwpw5i

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

17 August 2017

PubMed publication ID

18044076

1 reference